OATP1B1 polymorphism as a determinant of erythromycin disposition

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 5, 2012, Pages 642-650

  Lancaster, C S ^a   Bruun, G H ^b   Peer, C J ^c   Mikkelsen, T S ^d   Corydon, T J ^b   Gibson, A A ^a   Hu, S ^a   Orwick, S J ^a   Mathijssen, R H J ^e   Figg, W D ^c   Baker, S D ^a   Sparreboom, A ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b AARHUS UNIVERSITY   (Denmark)

^c NATIONAL CANCER INSTITUTE   (United States)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROMYCIN; OATP1B1 PROTEIN; POLYPEPTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG DISPOSITION; DRUG METABOLISM; FEMALE; GENE FUNCTION; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; METABOLIC RATE; MICHAELIS CONSTANT; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTI-BACTERIAL AGENTS; BIOLOGICAL TRANSPORT; CELL LINE; CYTOCHROME P-450 CYP3A; ERYTHROMYCIN; FEMALE; HUMANS; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; POLYMORPHISM, GENETIC;

EID: 84867886820     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.106     Document Type: Article

References (43)

1. Opdam, F.L., Gelderblom, H. & Guchelaar, H.J. Phenotyping drug disposition in oncology. Cancer Treat. Rev. 38, 715-725 (2012).
2. Watkins, P.B. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 4, 171-184 (1994). (Pubitemid 24269821)
3. Baker, S.D. et al. Factors affecting cytochrome P-450 3A activity in cancer patients. Clin. Cancer Res. 10, 8341-8350 (2004). (Pubitemid 40053395)
4. Baker, S.D. et al. Pharmacogenetic pathway analysis of docetaxel elimination. Clin. Pharmacol. Ther. 85, 155-163 (2009).
5. Kurnik, D., Wood, A.J. & Wilkinson, G.R. The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity. Clin. Pharmacol. Ther. 80, 228-234 (2006). (Pubitemid 44301092)
6. Lan, L.B., Dalton, J.T. & Schuetz, E.G. Mdr1 limits CYP3A metabolism in vivo. Mol. Pharmacol. 58, 863-869 (2000).
7. Franke, R.M. et al. Effect of ABCC2 (MRP2) transport function on erythromycin metabolism. Clin. Pharmacol. Ther. 89, 693-701 (2011).
8. Fattinger, K., Cattori, V., Hagenbuch, B., Meier, P.J. & Stieger, B. Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2. Hepatology 32, 82-86 (2000). (Pubitemid 30432369)
9. Lam, J.L., Okochi, H., Huang, Y. & Benet, L.Z. In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: characterizing the importance of transporter-enzyme interplay. Drug Metab. Dispos. 34, 1336-1344 (2006). (Pubitemid 44079874)
10. Frassetto, L.A., Poon, S., Tsourounis, C., Valera, C. & Benet, L.Z. Effects of uptake and efflux transporter inhibition on erythromycin breath test results. Clin. Pharmacol. Ther. 81, 828-832 (2007). (Pubitemid 46788293)
11. Nelson, M.V., Berchou, R.C., Kareti, D. & LeWitt, P.A. Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine. Clin. Pharmacol. Ther. 47, 694-697 (1990). (Pubitemid 20207326)
12. Lu, W.J., Huang, K., Lai, M.L. & Huang, J.D. Erythromycin alters the pharmacokinetics of bromocriptine by inhibition of organic anion transporting polypeptide C-mediated uptake. Clin. Pharmacol. Ther. 80, 421-422 (2006). (Pubitemid 44465885)
13. Franke, R.M., Baker, S.D., Mathijssen, R.H., Schuetz, E.G. & Sparreboom, A. Influence of solute carriers on the pharmacokinetics of CYP3A4 probes. Clin. Pharmacol. Ther. 84, 704-709 (2008).
14. Franke, R.M., Carducci, M.A., Rudek, M.A., Baker, S.D. & Sparreboom, A. Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J. Clin. Oncol. 28, 4562-4567 (2010).
15. Ramsey, L.B. et al. Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res. 22, 1-8 (2012).
16. Roth, M., Obaidat, A. & Hagenbuch, B. OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br. J. Pharmacol. 165, 1260-1287 (2012).
17. Iusuf, D., van de Steeg, E. & Schinkel, A.H. Functions of OATP1A and 1B transporters in vivo: insights from mouse models. Trends Pharmacol. Sci. 33, 100-108 (2012).
18. Kameyama, Y., Yamashita, K., Kobayashi, K., Hosokawa, M. & Chiba, K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet. Genomics 15, 513-522 (2005). (Pubitemid 41017600)
19. Watkins, P.B., Murray, S.A., Winkelman, L.G., Heuman, D.M., Wrighton, S.A. & Guzelian, P.S. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. J. Clin. Invest. 83, 688-697 (1989). (Pubitemid 19061193)
20. Hunt, C.M., Westerkam, W.R. & Stave, G.M. Effect of age and gender on the activity of human hepatic CYP3A. Biochem. Pharmacol. 44, 275-283 (1992).
21. Floyd, M.D. et al. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European-and African-American men and women. Pharmacogenetics 13, 595-606 (2003). (Pubitemid 37311146)
22. Rivory, L.P., Slaviero, K.A., Hoskins, J.M. & Clarke, S.J. The erythromycin breath test for the prediction of drug clearance. Clin. Pharmacokinet. 40, 151-158 (2001). (Pubitemid 32324447)
23. Treviño, L.R. et al. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J. Clin. Oncol. 27, 5972-5978 (2009).
24. Kim, S.R. et al. Genetic variations and frequencies of major haplotypes in SLCO1B1 encoding the transporter OATP1B1 in Japanese subjects: SLCO1B1 17 is more prevalent than 15. Drug Metab. Pharmacokinet. 22, 456-461 (2007).
25. van de Steeg, E. et al. Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. J Clin Invest 122, 519-528 (2012).
26. Chhun, S. et al. Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers. Br. J. Clin. Pharmacol. 68, 226-237 (2009).
27. Chugh, R. et al. Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma. Cancer 109, 2315-2322 (2007). (Pubitemid 46801563)
28. Gurney, H. et al. Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clin. Pharmacol. Ther. 82, 33-40 (2007). (Pubitemid 46944197)
29. Mathijssen, R.H. et al. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J. Natl. Cancer Inst. 96, 1585-1592 (2004).
30. Schott, A.F., Rae, J.M., Griffith, K.A., Hayes, D.F., Sterns, V. & Baker, L.H. Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme. Cancer Chemother. Pharmacol. 58, 129-135 (2006).
31. Hu, S. et al. Interaction of imatinib with human organic ion carriers. Clin. Cancer Res. 14, 3141-3148 (2008).
32. Smith, N.F., Figg, W.D. & Sparreboom, A. Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opin. Drug Metab. Toxicol. 1, 429-445 (2005).
33. Slaviero, K.A., Clarke, S.J., McLachlan, A.J., Blair, E.Y. & Rivory, L.P. Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. Br. J. Clin. Pharmacol. 57, 44-53 (2004). (Pubitemid 38067949)
34. Hirth, J., Watkins, P.B., Strawderman, M., Schott, A., Bruno, R. & Baker, L.H. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin. Cancer Res. 6, 1255-1258 (2000). (Pubitemid 30226205)
35. Hooker, A.C. et al. Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements. Clin. Pharmacol. Ther. 84, 111-118 (2008). (Pubitemid 351861492)
36. Hurria, A. et al. Pharmacokinetics and toxicity of weekly docetaxel in older patients. Clin. Cancer Res. 12, 6100-6105 (2006). (Pubitemid 44703775)
37. Michael, M. et al. Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C(14)-erythromycin breath test and the antipyrine clearance test. Cancer Chemother. Pharmacol. 69, 125-135 (2012).
38. Kovarik, J.M., Beyer, D., Bizot, M.N., Jiang, Q., Shenouda, M. & Schmouder, R.L. Effect of multiple-dose erythromycin on everolimus pharmacokinetics. Eur. J. Clin. Pharmacol. 61, 35-38 (2005). (Pubitemid 40558277)
39. Bruno, R., Vivier, N., Veyrat-Follet, C., Montay, G. & Rhodes, G.R. Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel. Invest. New Drugs 19, 163-169 (2001). (Pubitemid 32423721)
40. Zaher, H. et al. Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin. Mol. Pharmacol. 74, 320-329 (2008).
41. Relling, M.V., McLeod, H.L., Bowman, L.C. & Santana, V.M. Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin. Clin. Pharmacol. Ther. 56, 503-511 (1994). (Pubitemid 24370357)
42. Rivory, L.P. et al. Optimizing the erythromycin breath test for use in cancer patients. Clin. Cancer Res. 6, 3480-3485 (2000).
43. Franke, R.M., Gardner, E.R. & Sparreboom, A. Pharmacogenetics of drug transporters. Curr. Pharm. Des. 16, 220-230 (2010).